Clinuvel Pharmaceuticals (ASX:CUV) Chief Executive Philippe Wolgen will be on a temporary leave of absence from his full duties due to health reasons, according to a Tuesday filing with the Australian bourse.
During Wolgen's absence, Chief Operations Officer Lachlan Hay will serve as acting CEO, with the executive team handling Wolgen's daily responsibilities for up to three months, the filing said.